Further positive results for ValiSeek VAL401 in Phase II trial for non-small cell lung cancer (NSCLC) patients. VAL401 treatment has a measureable improvement on patient Quality of Life, in addition to a significant impact on survival. London, Paris and Boston, 16 January 2018: Ariana Pharma and ValiRx Plc (AIM: VAL), the clinical stage biotechnology company, today provided an update on the clinical progress and results of VAL401, the anti-cancer compound developed by ValiSeek. Following on from the announcement on 12 December 2017 regarding the overall survival results from the completed Phase II Clinical Trial of VAL401 in Tbilisi, Georgia, in the treatment of late stage non-small [...]